{"id":"NCT00750880","sponsor":"Hoffmann-La Roche","briefTitle":"An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.","officialTitle":"International Multi-Center Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have An Inadequate Response to Current Non-Biologic DMARD or Anti-TNF Therapy.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2011-07","completion":"2011-07","firstPosted":"2008-09-11","resultsPosted":"2014-08-07","lastUpdate":"2015-07-22"},"enrollment":1681,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"This open-label, single arm study will investigate the safety, tolerability and efficacy of tocilizumab monotherapy, or combination therapy with non-biologic disease modifying antirheumatic drugs (DMARDs), in patients with severe active RA. Patients will receive tocilizumab 8mg/kg iv as a 60 minute infusion every 4 weeks for a total of 6 infusions. The anticipated time on study treatment is 3-12 months, and the target sample size is \\>500 individuals.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs): Overall Summary","timeFrame":"Weeks 4, 8, 12, 16, 20, and 24","effectByArm":[{"arm":"Tocilizumab 8 mg/kg","deltaMin":77.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":282,"countries":["Australia","Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","India","Ireland","Italy","Luxembourg","Netherlands","Poland","Portugal","Romania","Saudi Arabia","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":131,"n":1681},"commonTop":["Nasopharyngitis","Blood cholesterol increased","Hypercholesterolaemia","Headache"]}}